Program Overview
This CME/CNE program will discuss recent advances in the treatment and management of multiple myeloma (MM) as presented at the American Society of Hematology 59th Annual Meeting & Exposition in Atlanta, Georgia. The expert faculty panel will provide learners with a scientific update regarding kidney toxicity, fractures, and other skeletal related events as they relate to MM patient care. Recent clinical trial data, particularly that pertaining to newly diagnosed patients, relapse refractory multiple myeloma and supportive care, will be analyzed and clinical relevance discussed. The expert faculty will review optimal means of incorporating newer therapies in practice utilizing a team-based approach to improve outcomes and quality of life in multiple myeloma patients. At the conclusion of this educational activity, learners will be better acquainted with optimal treatment, monitoring and management techniques for patients with MM.
Target Audience
Hematologists/oncologists, internists, nurse practitioners, nurses and other healthcare providers responsible for the management of patients with multiple myeloma
Learning Objectives
1. Discuss the comorbidities of multiple myeloma, including kidney toxicity, fractures, and other skeletal related events
2. Analyze clinical trial data related to the treatment of multiple myeloma as presented at ASH 2017
3. Incorporate newer therapies to improve outcomes and quality of life in patients with multiple myeloma using a team-based approach
Faculty
Ola Landgren, MD, PhD
Chief of Myeloma Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Suzanne Lentzsch, MD, PhD
Division of Hematology/Oncology
Herbert Irving Comprehensive Cancer Center
New York Presbyterian Hospital/ Columbia University Medical Center
Director, Multiple Myeloma and Amyloidosis Program
Professor of Clinical Medicine
Columbia University
New York, New York
Beth Faiman, PhD, MSN, APN-BC, AOCN
Nurse Practitioner
Department of Hematologic Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| C. Ola Landgren, MD, PhD | Nothing to disclose. |
| Suzanne Lentzsch, MD, PhD | Consultant/Advisor: Bayer AG; Caelum Biosciences; Janssen Pharmaceuticals, Inc. |
| Beth Faiman, PhD, MSN, APN-BC, AOCN | Consultant/Advisor: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceutical Company Limited |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).
Financial Support
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
